Clinical Trial Update: Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of irinotecan, carboplatin, and bevacizumab for extensive-stage small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)
• Paraplatin (Carboplatin)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Carcinoma, Small Cell Lung | Phase 2 | Status: COMPLETED